First biologic drug in the treatment of RAS wild-type metastatic colorectal cancer: Anti-EGFR or Bevacizumab? Results from a meta-analysis

Research output: Contribution to journalReview article

Abstract

Introduction: We performed a meta-analysis in order to analyze and quantify the effect on survival of starting therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients with anti-EGFR agents or bevacizumab. Patients and Methods: Randomized, phase II or III, clinical trials reporting overall survival (OS) in RAS wt mCRC patients treated with first-line chemotherapy (CT) associated with bevacizumab or anti-EGFR agents were selected. The primary end-point of this meta-analysis was OS; findings were depicted in classical Forest plots. Results: Seven studies met the criteria for meta-analysis including 3,805 patients. The pooled second-line cross-over rate to bevacizumab was 36.6%, to anti-EGFR 33.2%. Only one study was selected reporting comparison between CT vs. CT plus bevacizumab in RAS wt patients with a HR of 1.13 in favor of CT (CI: 0.89-1.43, p = 0.317). The pooled HRs were 0.89 (95% CI: 0.79-1.00) for CT plus anti-EGFR vs. CT and 0.81 (95% CI: 0.71-0.92) in favor of CT plus anti-EGFR vs. CT plus bevacizumab. Subgroup analysis showed a positive prognostic impact of starting CT plus anti-EGFR in left colon cancer (pooled HR: 0.70; CI: 0.54-0.85) while a positive trend of starting CT plus bevacizumab was observed in right colon cancer (pooled HR: 1.29; CI: 0.81-1.77). Conclusions: This meta-analysis shows that starting therapy in RAS wt mCRC patients with an anti-EGFR agent improves OS when the primary tumor location is in the left colon but a strong limitation of previous studies is the very low rate of biologic drug therapy cross-over.

Original languageEnglish
Article number441
JournalFrontiers in Pharmacology
Volume9
Issue numberMAY
DOIs
Publication statusPublished - May 3 2018

Fingerprint

Meta-Analysis
Colorectal Neoplasms
Drug Therapy
Pharmaceutical Preparations
Therapeutics
Survival
Colonic Neoplasms
Bevacizumab
Biological Therapy
Colon
Clinical Trials

Keywords

  • Bevacizumab
  • Cetuximab
  • Chemotherapy
  • Colorectal carcinoma
  • Panitumumab

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{79682f5e5bee49beac9e3791d836753e,
title = "First biologic drug in the treatment of RAS wild-type metastatic colorectal cancer: Anti-EGFR or Bevacizumab? Results from a meta-analysis",
abstract = "Introduction: We performed a meta-analysis in order to analyze and quantify the effect on survival of starting therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients with anti-EGFR agents or bevacizumab. Patients and Methods: Randomized, phase II or III, clinical trials reporting overall survival (OS) in RAS wt mCRC patients treated with first-line chemotherapy (CT) associated with bevacizumab or anti-EGFR agents were selected. The primary end-point of this meta-analysis was OS; findings were depicted in classical Forest plots. Results: Seven studies met the criteria for meta-analysis including 3,805 patients. The pooled second-line cross-over rate to bevacizumab was 36.6{\%}, to anti-EGFR 33.2{\%}. Only one study was selected reporting comparison between CT vs. CT plus bevacizumab in RAS wt patients with a HR of 1.13 in favor of CT (CI: 0.89-1.43, p = 0.317). The pooled HRs were 0.89 (95{\%} CI: 0.79-1.00) for CT plus anti-EGFR vs. CT and 0.81 (95{\%} CI: 0.71-0.92) in favor of CT plus anti-EGFR vs. CT plus bevacizumab. Subgroup analysis showed a positive prognostic impact of starting CT plus anti-EGFR in left colon cancer (pooled HR: 0.70; CI: 0.54-0.85) while a positive trend of starting CT plus bevacizumab was observed in right colon cancer (pooled HR: 1.29; CI: 0.81-1.77). Conclusions: This meta-analysis shows that starting therapy in RAS wt mCRC patients with an anti-EGFR agent improves OS when the primary tumor location is in the left colon but a strong limitation of previous studies is the very low rate of biologic drug therapy cross-over.",
keywords = "Bevacizumab, Cetuximab, Chemotherapy, Colorectal carcinoma, Panitumumab",
author = "Alessandro Ottaiano and {De Stefano}, Alfonso and Monica Capozzi and Anna Nappi and {De Divitiis}, Chiara and Carmela Romano and Lucrezia Silvestro and Antonino Cassata and Rossana Casaretti and Salvatore Tafuto and Michele Caraglia and Massimiliano Berretta and Guglielmo Nasti and Antonio Avallone",
year = "2018",
month = "5",
day = "3",
doi = "10.3389/fphar.2018.00441",
language = "English",
volume = "9",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",
number = "MAY",

}

TY - JOUR

T1 - First biologic drug in the treatment of RAS wild-type metastatic colorectal cancer

T2 - Anti-EGFR or Bevacizumab? Results from a meta-analysis

AU - Ottaiano, Alessandro

AU - De Stefano, Alfonso

AU - Capozzi, Monica

AU - Nappi, Anna

AU - De Divitiis, Chiara

AU - Romano, Carmela

AU - Silvestro, Lucrezia

AU - Cassata, Antonino

AU - Casaretti, Rossana

AU - Tafuto, Salvatore

AU - Caraglia, Michele

AU - Berretta, Massimiliano

AU - Nasti, Guglielmo

AU - Avallone, Antonio

PY - 2018/5/3

Y1 - 2018/5/3

N2 - Introduction: We performed a meta-analysis in order to analyze and quantify the effect on survival of starting therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients with anti-EGFR agents or bevacizumab. Patients and Methods: Randomized, phase II or III, clinical trials reporting overall survival (OS) in RAS wt mCRC patients treated with first-line chemotherapy (CT) associated with bevacizumab or anti-EGFR agents were selected. The primary end-point of this meta-analysis was OS; findings were depicted in classical Forest plots. Results: Seven studies met the criteria for meta-analysis including 3,805 patients. The pooled second-line cross-over rate to bevacizumab was 36.6%, to anti-EGFR 33.2%. Only one study was selected reporting comparison between CT vs. CT plus bevacizumab in RAS wt patients with a HR of 1.13 in favor of CT (CI: 0.89-1.43, p = 0.317). The pooled HRs were 0.89 (95% CI: 0.79-1.00) for CT plus anti-EGFR vs. CT and 0.81 (95% CI: 0.71-0.92) in favor of CT plus anti-EGFR vs. CT plus bevacizumab. Subgroup analysis showed a positive prognostic impact of starting CT plus anti-EGFR in left colon cancer (pooled HR: 0.70; CI: 0.54-0.85) while a positive trend of starting CT plus bevacizumab was observed in right colon cancer (pooled HR: 1.29; CI: 0.81-1.77). Conclusions: This meta-analysis shows that starting therapy in RAS wt mCRC patients with an anti-EGFR agent improves OS when the primary tumor location is in the left colon but a strong limitation of previous studies is the very low rate of biologic drug therapy cross-over.

AB - Introduction: We performed a meta-analysis in order to analyze and quantify the effect on survival of starting therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients with anti-EGFR agents or bevacizumab. Patients and Methods: Randomized, phase II or III, clinical trials reporting overall survival (OS) in RAS wt mCRC patients treated with first-line chemotherapy (CT) associated with bevacizumab or anti-EGFR agents were selected. The primary end-point of this meta-analysis was OS; findings were depicted in classical Forest plots. Results: Seven studies met the criteria for meta-analysis including 3,805 patients. The pooled second-line cross-over rate to bevacizumab was 36.6%, to anti-EGFR 33.2%. Only one study was selected reporting comparison between CT vs. CT plus bevacizumab in RAS wt patients with a HR of 1.13 in favor of CT (CI: 0.89-1.43, p = 0.317). The pooled HRs were 0.89 (95% CI: 0.79-1.00) for CT plus anti-EGFR vs. CT and 0.81 (95% CI: 0.71-0.92) in favor of CT plus anti-EGFR vs. CT plus bevacizumab. Subgroup analysis showed a positive prognostic impact of starting CT plus anti-EGFR in left colon cancer (pooled HR: 0.70; CI: 0.54-0.85) while a positive trend of starting CT plus bevacizumab was observed in right colon cancer (pooled HR: 1.29; CI: 0.81-1.77). Conclusions: This meta-analysis shows that starting therapy in RAS wt mCRC patients with an anti-EGFR agent improves OS when the primary tumor location is in the left colon but a strong limitation of previous studies is the very low rate of biologic drug therapy cross-over.

KW - Bevacizumab

KW - Cetuximab

KW - Chemotherapy

KW - Colorectal carcinoma

KW - Panitumumab

UR - http://www.scopus.com/inward/record.url?scp=85046625470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046625470&partnerID=8YFLogxK

U2 - 10.3389/fphar.2018.00441

DO - 10.3389/fphar.2018.00441

M3 - Review article

AN - SCOPUS:85046625470

VL - 9

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - MAY

M1 - 441

ER -